Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a federal judge denied a motion filed by a compounding trade group over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) ...
Zacks Investment Research on MSN
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company’s launch of a new menopause and perimenopause care specialty on its Hers platform. What Happened: Hims & ...
Hims & Hers stock jumped 6% in post-market trading Monday after the company said it was in active discussions to make Wegovy injections and Novo Nordisk’s forthcoming obesity pill available through ...
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, ...
The call centered around Hims & Hers’ push beyond treatment into proactive and personalized health management. Dudum confirmed plans to launch whole-body lab testing before year-end, followed by a new ...
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback